
Exelixis (EXEL) Stock Forecast & Price Target
Exelixis (EXEL) Analyst Ratings
Bulls say
Exelixis is a highly promising biopharmaceutical firm with strong molecules such as cabozantinib and Cotellic, slated for further development and approval by mid-2026. With a solid 4 times increase in revenue to $610.8 million and a promising cash position of ~$1.43 billion in cash, cash equivalents and marketable securities, and plans to complete the $750 million stock repurchase program in May 2026, Exelixis can continue to deliver strong EPS growth rates for the coming years.
Bears say
Exelixis is facing financial struggles as evidenced by the impairment of long-lived assets in 2026 and the need for additional stock repurchase authorizations to provide EPS support. In addition, the upcoming catalysts highlighted may not be enough to offset the potential negative impact of decreased materiality in their ESG performance for investors.
This aggregate rating is based on analysts' research of Exelixis and is not a guaranteed prediction by Public.com or investment advice.
Exelixis (EXEL) Analyst Forecast & Price Prediction
Start investing in Exelixis (EXEL)
Order type
Buy in
Order amount
Est. shares
0 shares